Press Releases

Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic diseases, today jointly announced an exclusive licensing agreement for Arctic Vision to develop and commercialize Olympic Ophthalmics' commercial stage product, iTEAR®100, for the treatment of dry eye disease in Greater China (mainland China, Hong Kon

Autoscribe Informatics, a leading global laboratory informatics provider, announced the release of a new and improved Matrix Gemini Pharmaceutical/Manufacturing LIMS to meet the changing needs of the pharmaceutical, manufacturing and regulated industries. Designed specifically for pharmaceutical and other regulated and non-regulated manufacturing industries the solution allows organisations to track the full batch manufacturing cycle. Full batch traceability allows the tracking of all raw mat

3M and Pandemic Action Network will collaborate on programs to help stem the spread of COVID-19 and today also announced a commitment to work together to help prepare for future pandemics. 3M has led a comprehensive global response to country-specific needs during the pandemic and will now combine its learnings with the insights from the Pandemic Action Network, the first organization of its kind to advocate for policy changes and increased support and resources to ensure countries

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, announced today that it has acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications. RIM Bio's Changzhou, China facility is Avantor's first single-use production plant in the AMEA region, building on the compa

Aptamer Group Limited, the developer of Optimer™ Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, today announce that they have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker. Optimer therapeuti

Samsung Biologics, a leading global CDMO providing end-to-end contract development and manufacturing services, today announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. As part of the company's long-ter

As a leader in cold chain packaging solutions, Lifoam Industries, LLC (Lifoam), a business segment and subsidiary of LifeMade Products LLC (LifeMade), is pleased to announce its increased supply of the versatile Envirocooler™ ActiVault™ portable refrigerated storage system in response to demand for COVID-19 vaccine distribution. Protecting temperature-sensitive pharmaceutical products requires reliable, specialized, and proven systems, and the portable, self-contained Ac

MEDISCA has finalized an exclusive distribution agreement with pharmaceutical manufacturer Sichuan Deebio Pharmaceutical Co., Ltd to provide thyroid active pharmaceutical ingredient (API) to the compounding and non-compounding industries in the United States. This agreement will bring much-needed stability to a market that has seen inconsistent supply for several years. “Compounding pharmacists have struggled to secure thyroid API for several years,” said Antonio Dos San

Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. Through this alliance, Eisai and ITO EN aim to contribute to the solution of dementia, which is one of the important social issues, with integrating Eisai's wealth of experience and knowledge in drug creation and disease aw

AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced that China's National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed to evaluate the safety and efficacy of AM006 in patients with early Parkinson's Disease (PD). AM006 is a novel non-ergot dopamine